ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy offers hope for transplant patients with rare Virus-Driven cancer
Disease control Recruiting nowThis study is testing an experimental cell therapy called tabelecleucel for transplant patients who develop a rare cancer caused by Epstein-Barr virus. The treatment uses specially prepared immune cells to target and fight the virus-related cancer in patients who haven't responde…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Could a lower dose of a harsh transplant drug be just as safe?
Disease control Recruiting nowThis study aims to find out if a lower dose of a key drug (cyclophosphamide) given after a stem cell transplant works as well as the standard dose to prevent graft-versus-host disease (GVHD). It will involve 316 patients receiving transplants from donors who are not a perfect mat…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Experimental cell therapy targets dangerous virus in vulnerable patients
Disease control Recruiting nowThis study is testing whether an experimental cell therapy called tabelecleucel can help control diseases caused by the Epstein-Barr virus in people with weakened immune systems. The trial includes 190 participants who have developed serious conditions like lymphomas or sarcomas …
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC